Drug news

European Commission approves Trazimera, biosimilar trastuzumab for HER2 overexpressing breast and gastric cancer.- Pfizer

Read time: 1 mins

Last updated:6th Sep 2018

Published:8th Aug 2018

Source: Pharmawand

Pfizer Inc. announced the European Commission (EC) has approved Trazimera a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

This approval follows the recommendation from the Committee for Medicinal Products for Human Use in May 2018.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news